{
    "id": 1324,
    "name": "lung cancer",
    "source": "DOID",
    "definition": "A respiratory system cancer that is located_in the lung. [url:http\\://en.wikipedia.org/wiki/Lung_cancer]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "06/25/2019",
    "altIds": [
        "13075",
        "9881",
        "1322"
    ],
    "termId": "DOID:1324",
    "evidence": [
        {
            "id": 305,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial of patients with advanced NSCLC, the combination of Cediranib (AZD-2171) and carboplatin/paclitaxel (CP) chemotherapy resulted in improved response rate over placebo plus CP, but did not improve progression-free survival, and the study did not proceed to Phase III due to toxicity (PMID: 24360368).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1664,
                "therapyName": "Carboplatin + Cediranib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 95,
                    "pubMedId": 24360368,
                    "title": "Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24360368"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 308,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rociletinib (CO-1686) induced tumor regression in EGFR-mutant human non-small cell lung cancer cell line xenograft models, while slightly inhibiting tumor growth in xenograft models of a wild-type EGFR human squamous carcinoma cell line (PMID: 24065731).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 157,
                    "pubMedId": 24065731,
                    "title": "Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24065731"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 314,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CUDC-101 inhibited the growth of lung cancer cells expressing EGFR T790M (PMID: 20388807).",
            "molecularProfile": {
                "id": 370,
                "profileName": "EGFR T790M"
            },
            "therapy": {
                "id": 1005,
                "therapyName": "CUDC-101",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 43,
                    "pubMedId": 20388807,
                    "title": "CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20388807"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 427,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Nerlynx (neratinib) administered with Torisel (temsirolimus) was tolerable and demonstrated antitumor activity in ERBB2 (HER2)-mutant non-small-cell lung cancer (PMID: 24323026).",
            "molecularProfile": {
                "id": 1216,
                "profileName": "ERBB2 mutant"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 94,
                    "pubMedId": 24323026,
                    "title": "Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24323026"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 431,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nintedanib, alone or with chemotherapy, inhibited tumor growth in cell line xenograft models of lung and pancreatic cancer but not in cell culture (PMID:23729403).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 81,
                    "pubMedId": 23729403,
                    "title": "BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23729403"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1288,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 reduced tumor size in mouse models of lung cancer carrying PIK3CA H1047R (PMID: 19029981).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 216,
                    "pubMedId": 19029981,
                    "title": "Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19029981"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1289,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sirolimus (rapamycin) did not induce tumor shrinkage in mouse lung cancer models carrying PIK3CA H1047R (PMID: 19029981).",
            "molecularProfile": {
                "id": 1731,
                "profileName": "PIK3CA H1047R"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 216,
                    "pubMedId": 19029981,
                    "title": "Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19029981"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8294,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 5339,
                "profileName": "EML4-ALK ALK G1202R"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2649,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, reduced proliferation, and induced apoptosis in transformed cells over expressing ALK G1202R in the context of EML4-ALK in culture and in cell line xenograft models (PMID: 26144315).",
            "molecularProfile": {
                "id": 5339,
                "profileName": "EML4-ALK ALK G1202R"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3367,
                    "pubMedId": 26144315,
                    "title": "PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26144315"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3541,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of lung cancer cells with FGFR1 amplification in culture (PMID: 22238366).",
            "molecularProfile": {
                "id": 812,
                "profileName": "FGFR1 amp"
            },
            "therapy": {
                "id": 996,
                "therapyName": "Brivanib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 311,
                    "pubMedId": 22238366,
                    "title": "Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22238366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3700,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination of Cediranib and Iressa (gefitinib) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including a partial response in a patient with lung cancer (PMID: 20061136).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3229,
                "therapyName": "Cediranib + Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3999,
                    "pubMedId": 20061136,
                    "title": "Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20061136"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4657,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the TTK (MPS1) inhibitor, SNG12, inhibited proliferation of lung cancer cells in culture and suppressed tumor growth in cell line xenograft models (PMID: 24900510).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3593,
                "therapyName": "SNG12",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4666,
                    "pubMedId": 24900510,
                    "title": "Diaminopyridine-based potent and selective mps1 kinase inhibitors binding to an unusual flipped-Peptide conformation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24900510"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5224,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cells treated with TAK-960 demonstrated a decrease in tumor size in cell line xenograft models (PMID: 22188812).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3780,
                "therapyName": "TAK-960",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4929,
                    "pubMedId": 22188812,
                    "title": "TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22188812"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5597,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD-1 antibodies were ineffective in treating Stk11 (also known as Lkb1) deficient lung tumors in mice (PMID: 26833127).",
            "molecularProfile": {
                "id": 1882,
                "profileName": "STK11 loss"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5119,
                    "pubMedId": 26833127,
                    "title": "STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26833127"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5831,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TPX-0005 inhibited Alk and Src signaling, and cell proliferation in lung cancer cell lines harboring EML4-ALK and elevated Src activity in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).",
            "molecularProfile": {
                "id": 21947,
                "profileName": "EML4-ALK SRC pos"
            },
            "therapy": {
                "id": 3950,
                "therapyName": "Repotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5176,
                    "pubMedId": null,
                    "title": "The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=055d4461-9793-4f83-b663-f356d9ae0fdb&cKey=ff6f8d25-f06a-4ae4-9dbf-7e390ef45123&mKey={1D10D749-4B6A-4AB3-BCD4-F80FB1922267}"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5835,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cell lines harboring EML4-ALK and elevated Src activity were resistant to Xalkori (crizotinib) induced growth inhibition in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).",
            "molecularProfile": {
                "id": 21947,
                "profileName": "EML4-ALK SRC pos"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5176,
                    "pubMedId": null,
                    "title": "The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=055d4461-9793-4f83-b663-f356d9ae0fdb&cKey=ff6f8d25-f06a-4ae4-9dbf-7e390ef45123&mKey={1D10D749-4B6A-4AB3-BCD4-F80FB1922267}"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6055,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, HD105 inhibited tumor progression in human lung cancer cell line xenograft models (PMID: 27049350).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4011,
                "therapyName": "HD105",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5258,
                    "pubMedId": 27049350,
                    "title": "Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27049350"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6116,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cells treated with VX-970 resulted in a synthetic lethal effect when combined with AZD7762, demonstrating increased survival and decreased tumor volume in xenograft models (PMID: 26748709).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4057,
                "therapyName": "AZD7762 + VX-970",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5316,
                    "pubMedId": 26748709,
                    "title": "Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26748709"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6160,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Xalkori (crizotinib) and Rubraca (rucaparib) synergized to inhibit growth of a Met-over expressing human lung cancer cell line in culture, and reduced tumor growth in xenograft models (PMID: 26779812).",
            "molecularProfile": {
                "id": 5392,
                "profileName": "MET over exp"
            },
            "therapy": {
                "id": 4070,
                "therapyName": "Crizotinib + Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5319,
                    "pubMedId": 26779812,
                    "title": "Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26779812"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6587,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABTL0812 inhibited growth and mTORC1 signaling and induced autophagy in a human lung cancer cell line in culture (PMID: 26671995).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2151,
                "therapyName": "ABTL0812",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5093,
                    "pubMedId": 26671995,
                    "title": "The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26671995"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6791,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 inhibited proliferation of lung cancer cell lines harboring FGFR1 amplification in culture and induced tumor regression in xenograft models (PMID: 23082000).",
            "molecularProfile": {
                "id": 812,
                "profileName": "FGFR1 amp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5821,
                    "pubMedId": 23082000,
                    "title": "Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23082000"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6867,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGFR1 non-amplified lung cancer cell lines demonstrated reduced sensitivity to AZD4547 induced growth inhibition in culture and in xenograft models (PMID: 23082000).",
            "molecularProfile": {
                "id": 542,
                "profileName": "FGFR1 wild-type"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5821,
                    "pubMedId": 23082000,
                    "title": "Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23082000"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6956,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 3148,
                "profileName": "ERBB2 Y772_A775dup"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6957,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 24125,
                "profileName": "ERBB2 G776delinsVC"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6958,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G776delinsLC in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 24128,
                "profileName": "ERBB2 G776delinsLC"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6959,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 3278,
                "profileName": "ERBB2 G778_P780dup"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6963,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 3148,
                "profileName": "ERBB2 Y772_A775dup"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6965,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G776delinsVC did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 24125,
                "profileName": "ERBB2 G776delinsVC"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6966,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G776delinsLC did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 24128,
                "profileName": "ERBB2 G776delinsLC"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6967,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 3278,
                "profileName": "ERBB2 G778_P780dup"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6969,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) V659E did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 11379,
                "profileName": "ERBB2 V659E"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6970,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, bronchial epithelial cells cells expressing ERBB2 (HER2) G660D did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 24165,
                "profileName": "ERBB2 G660D"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6971,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) V659E in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 11379,
                "profileName": "ERBB2 V659E"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14509,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gilotrif (afatinib) treatment resulted in partial response in the lung lesion and stable bone metastasis for over 16 months in a patient with familial lung cancer harboring germline ERBB2 G660D mutation (PMID: 29146616).",
            "molecularProfile": {
                "id": 24165,
                "profileName": "ERBB2 G660D"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11692,
                    "pubMedId": 29146616,
                    "title": "Therapeutic Potential of Afatinib for Cancers with ERBB2 (HER2) Transmembrane Domain Mutations G660D and V659E.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29146616"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6972,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G660D in culture (PMID: 26545934).",
            "molecularProfile": {
                "id": 24165,
                "profileName": "ERBB2 G660D"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5974,
                    "pubMedId": 26545934,
                    "title": "Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26545934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15490,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a patient with lung cancer harboring a germline mutation, ERBB2 (HER2) G660D, demonstrated improved symptoms within 30 days of Gilotrif (afatinib) treatment, as well as a 21% reduction in tumor volume in 12 weeks and a durable response that lasted for more than 15 weeks (PMID: 30449325).",
            "molecularProfile": {
                "id": 24165,
                "profileName": "ERBB2 G660D"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13125,
                    "pubMedId": 30449325,
                    "title": "Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30449325"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7134,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of lung cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).",
            "molecularProfile": {
                "id": 5943,
                "profileName": "NOTCH1 positive"
            },
            "therapy": {
                "id": 2958,
                "therapyName": "LY3039478",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3325,
                    "pubMedId": null,
                    "title": "Abstract 1131: Novel inhibitor of Notch signaling for the treatment of cancer.",
                    "url": "http://cancerres.aacrjournals.org/content/73/8_Supplement/1131.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7333,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed lung cancer cells over expressing ERBB2 (HER2) T798I were resistant to Tykerb (lapatinib) in culture (PMID: 25238247).",
            "molecularProfile": {
                "id": 24613,
                "profileName": "ERBB2 T798I"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6146,
                    "pubMedId": 25238247,
                    "title": "Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25238247"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7594,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment induced tumor regression in an EGFR L858R/T790M-mutant-driven lung cancer mouse model (PMID: 27251290).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 4521,
                "therapyName": "Cetuximab + EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6436,
                    "pubMedId": 27251290,
                    "title": "Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27251290"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7595,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment did not induced response in an EGFR exon 19 deletion/T790M-driven lung cancer mouse model (PMID: 27251290).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 4521,
                "therapyName": "Cetuximab + EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6436,
                    "pubMedId": 27251290,
                    "title": "Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27251290"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7596,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment induced tumor regression in an EGFR L858R/T790M/C797S-mutant-driven lung cancer mouse model (PMID: 27251290).",
            "molecularProfile": {
                "id": 14859,
                "profileName": "EGFR C797S EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 4521,
                "therapyName": "Cetuximab + EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6436,
                    "pubMedId": 27251290,
                    "title": "Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27251290"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7672,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Platinol (cisplatin) and CBP501 resulted in enhanced tumor growth inhibition in cell line xenograft models of lung cancer, compared to either agent alone (PMID: 17237275).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4547,
                "therapyName": "CBP501 + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6450,
                    "pubMedId": 17237275,
                    "title": "Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17237275"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7723,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human lung cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299).",
            "molecularProfile": {
                "id": 2242,
                "profileName": "EGFR pos ERBB2 pos"
            },
            "therapy": {
                "id": 1048,
                "therapyName": "S-222611",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1835,
                    "pubMedId": 24837299,
                    "title": "Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24837299"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7731,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR125844 inhibited Met signaling, leading to growth inhibition of MET amplified lung cancer cells in culture (PMID: 25504634).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 2159,
                "therapyName": "SAR125844",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2009,
                    "pubMedId": 25504634,
                    "title": "The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25504634"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8065,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB-283 inhibited proliferation of Egfr over expressing lung cancer cells in culture (PMID: 26208524).",
            "molecularProfile": {
                "id": 2419,
                "profileName": "EGFR over exp"
            },
            "therapy": {
                "id": 4025,
                "therapyName": "BGB-283",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5280,
                    "pubMedId": 26208524,
                    "title": "BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26208524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8249,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type lung cancer cell lines in culture (PMID: 26162687).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "AMG 232",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8255,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TP53-null lung cancer cells were resistant to AMG 232 induced growth inhibition in culture (PMID: 26162687).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "AMG 232",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8256,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type lung cancer cell lines in culture and in cell line xenograft models (PMID: 26162687).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 4671,
                "therapyName": "AMG 232 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8261,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 232 did not enhance radiation-induced cytotoxicity in TP53-null lung cancer cells in culture and in cell line xenograft models (PMID: 26162687).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 4671,
                "therapyName": "AMG 232 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8279,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Apatinib (YN968D1) inhibited tumor growth in lung cancer cell line xenograft models (PMID: 21443688).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 986,
                "therapyName": "Apatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 592,
                    "pubMedId": 21443688,
                    "title": "YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21443688"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9028,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 337 inhibited growth of MET-amplified lung cancer cell lines in culture (PMID: 27196782).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6878,
                    "pubMedId": 27196782,
                    "title": "In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196782"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9074,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, sensitivity to PU-H71 was correlated to presence of the epichaperome, a network of chaperome complexes, in lung cancer cell lines in culture (PMID: 27706135).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1162,
                "therapyName": "PU-H71",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6895,
                    "pubMedId": 27706135,
                    "title": "The epichaperome is an integrated chaperome network that facilitates tumour survival.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27706135"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9143,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Dinaciclib (SCH 727965) and Taxol (paclitaxel) demonstrated enhanced growth inhibition in lung cancer cell lines in culture (PMID: 27550941).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4912,
                "therapyName": "Dinaciclib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6931,
                    "pubMedId": 27550941,
                    "title": "Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550941"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9566,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3759 inhibited EGFR activation and growth of a lung cancer cell line harboring EGFR L858R in culture, and inhibited tumor growth in xenograft models (PMID: 27928026).",
            "molecularProfile": {
                "id": 369,
                "profileName": "EGFR L858R"
            },
            "therapy": {
                "id": 2912,
                "therapyName": "AZD3759",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7282,
                    "pubMedId": 27928026,
                    "title": "AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27928026"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9567,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, treatment with AZD3759 inhibited EGFR activity and demonstrated antitumor activity in two patients with non-small cell lung cancer harboring EGFR L858R, resulting in decreased CSF tumor cell number in the patient with leptomeningeal metastasis, and decreased brain tumor growth in the patient with brain metastasis (PMID: 27928026).",
            "molecularProfile": {
                "id": 369,
                "profileName": "EGFR L858R"
            },
            "therapy": {
                "id": 2912,
                "therapyName": "AZD3759",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7282,
                    "pubMedId": 27928026,
                    "title": "AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27928026"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9568,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3759 inhibited EGFR activation and growth of a lung cancer cell line harboring an EGFR exon 19 deletion in culture and induced tumor regression in subcutaneous xenograft models, and inhibited tumor growth in brain and leptomeningeal xenograft models (PMID: 27928026).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 2912,
                "therapyName": "AZD3759",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7282,
                    "pubMedId": 27928026,
                    "title": "AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27928026"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9569,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line harboring EGFR L858R and T790M did not demonstrate sensitivity to AZD3759 in culture (PMID: 27928026).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 2912,
                "therapyName": "AZD3759",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7282,
                    "pubMedId": 27928026,
                    "title": "AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27928026"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9722,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, treatment with Cometriq (cabozantinib) resulted in an overall response rate of 28% (7/25) in patients with RET-rearranged lung cancer (PMID: 27825636).",
            "molecularProfile": {
                "id": 1326,
                "profileName": "RET rearrange"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 7513,
                    "pubMedId": 27825636,
                    "title": "Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27825636"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16159,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, multikinase inhibitor treatment demonstrated suboptimal clinical efficacy in RET-rearranged lung cancer patients with measurable baseline brain metastasis, resulted in confirmed intracranial response in 18% (2/11) of the patients; Cometriq (cabozantinib) treatment resulted in no intracranial response in 3 patients (PMID: 30017832).",
            "molecularProfile": {
                "id": 1326,
                "profileName": "RET rearrange"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 14285,
                    "pubMedId": 30017832,
                    "title": "Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30017832"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9743,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of ABT-737 and perifosine worked synergistically to induce apoptosis and inhibit growth of lung cancer cell lines and primary lung cancer cells in culture, and to inhibit tumor growth in a lung cancer cell line xenograft model (PMID: 27073162).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5187,
                "therapyName": "ABT-737 + Perifosine",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7520,
                    "pubMedId": 27073162,
                    "title": "Perifosine and ABT-737 synergistically inhibit lung cancer cells in\u00a0vitro and in\u00a0vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27073162"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9828,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Glucophage (metformin) inhibited proliferation of several lung cancer cell lines in culture, including squamous, adenocarcinoma, large cell, and small celll lung cancer cell lines (PMID: 22576795).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1031,
                "therapyName": "Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7651,
                    "pubMedId": 22576795,
                    "title": "Antiproliferative action of metformin in human lung cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22576795"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10260,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of CDKN2A-deleted lung cancer (PMID: 26140595).",
            "molecularProfile": {
                "id": 6542,
                "profileName": "CDKN2A del"
            },
            "therapy": {
                "id": 5443,
                "therapyName": "PF-00477736 + PF3644022",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8232,
                    "pubMedId": 26140595,
                    "title": "A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26140595"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10335,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CT16 treatment decreased NOTCH and EGFR signaling and inhibited tumor growth in lung cancer patient-derived xenograft (PDX) models sensitive to EGFR blockade (PMID: 28275151).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5472,
                "therapyName": "CT16",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8315,
                    "pubMedId": 28275151,
                    "title": "Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28275151"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10343,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, X-376 inhibited Alk signaling, resulted in growth inhibition in lung cancer cells harboring EML4-ALK fusion in culture and in cell line xenograft models (PMID: 21613408).",
            "molecularProfile": {
                "id": 4138,
                "profileName": "EML4-ALK"
            },
            "therapy": {
                "id": 2520,
                "therapyName": "X-376",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2442,
                    "pubMedId": 21613408,
                    "title": "Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21613408"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10680,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TC-A2317 inhibited growth, induced apoptosis in lung cancer cell lines in culture (PMID: 27713168).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5579,
                "therapyName": "TC-A2317",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8740,
                    "pubMedId": 27713168,
                    "title": "The Aurora kinase A inhibitor TC-A2317 disrupts mitotic progression and inhibits cancer cell proliferation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27713168"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10757,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Golvatinib (E7050) inhibited Met and Kdr (Vegfr2) phosphorylation, resulted in growth inhibition of lung cancer cells in culture and tumor regression in cell line xenograft models (PMID: 19832844).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1019,
                "therapyName": "Golvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 41,
                    "pubMedId": 19832844,
                    "title": "E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19832844"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11124,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Mekinist (trametinib) and AZ628 resulted in greater inhibition of Mek and apoptosis in a non-BRAF V600 mutant lung cancer cell line in culture compared to the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) (J Clin Oncol 35, 2017 (suppl; abstr e23154)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4795,
                "therapyName": "AZ628 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9096,
                    "pubMedId": null,
                    "title": "Type II RAF inhibition predicts superior ERK suppression compared to type I RAF inhibition in different BRAF mutant types recurrently found in lung cancer",
                    "url": "http://abstracts.asco.org/199/AbstView_199_191661.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11179,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Balversa (erdafitinib) inhibited FGFR downstream signaling and proliferation of several lung cancer cell lines with FGFR1 amplification in culture, and inhibited tumor growth in an FGFR1-amplified lung cancer cell line xenograft model (PMID: 28341788).",
            "molecularProfile": {
                "id": 812,
                "profileName": "FGFR1 amp"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9140,
                    "pubMedId": 28341788,
                    "title": "Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28341788"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11184,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cell lines with co-amplification of FGFR1 and EGFR demonstrated insensitivity to Balversa (erdafitinib) in culture (PMID: 28341788).",
            "molecularProfile": {
                "id": 27922,
                "profileName": "EGFR amp FGFR1 amp"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9140,
                    "pubMedId": 28341788,
                    "title": "Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28341788"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11303,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tagrisso (osimertinib) and Sprycel (dasatinib) in combination resulted in increased PARP cleavage and inhibition of proliferation in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M compared to Tagrisso (osimertinib) alone, and inhibited tumor growth in xenograft models, with 3 out of 7 models demonstrating no tumor rebound after cessation of therapy (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 4946,
                "therapyName": "Dasatinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11304,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Buparlisib (BKM120) and Tagrisso (osimertinib) resulted in increased inhibition of AKT phosphorylation and proliferation compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 5935,
                "therapyName": "Buparlisib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11305,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of GSK2334470 and Tagrisso (osimertinib) resulted in increased inhibition of AKT phosphorylation and proliferation compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 5936,
                "therapyName": "GSK2334470 + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11306,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of TAK-632 and Tagrisso (osimertinib) resulted in increased inhibition of ERK phosphorylation and proliferation compared to either agent alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 5937,
                "therapyName": "Osimertinib + TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11307,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Selumetinib (AZD6244) and Tagrisso (osimertinib) resulted in increased inhibition of ERK phosphorylation and proliferation compared to either agent alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 2225,
                "therapyName": "Osimertinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11308,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tagrisso (osimertinib) with PF-573328 and Saracatinib (AZD0530) resulted in increased inhibition of AKT, FAK, and SFK phosphorylation and growth compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 5938,
                "therapyName": "Osimertinib + PF-573228 + Saracatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11309,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tagrisso (osimertinib) with PF-573328 and Bosulif (bosutinib) resulted in increased inhibition of AKT, FAK, and SFK phosphorylation and growth compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 5939,
                "therapyName": "Bosutinib + Osimertinib + PF-573228",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11310,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Buparlisib (BKM-120) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 369,
                "profileName": "EGFR L858R"
            },
            "therapy": {
                "id": 5935,
                "therapyName": "Buparlisib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11311,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Selumetinib (AZD6244) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 369,
                "profileName": "EGFR L858R"
            },
            "therapy": {
                "id": 2225,
                "therapyName": "Osimertinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11312,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sprycel (dasatinib) to treatment with Tagrisso (osimertinib) resulted in increased PARP cleavage and inhibition of proliferation in lung cancer cell lines harboring EGFR L858R in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 369,
                "profileName": "EGFR L858R"
            },
            "therapy": {
                "id": 4600,
                "therapyName": "Dasatinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11313,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sprycel (dasatinib) to treatment with Tagrisso (osimertinib) resulted in increased PARP cleavage and inhibition of proliferation in lung cancer cell lines harboring EGFR L858R and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 4946,
                "therapyName": "Dasatinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11314,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Selumetinib (AZD6244) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 2225,
                "therapyName": "Osimertinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11315,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Buparlisib (BKM-120) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 5935,
                "therapyName": "Buparlisib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11317,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Selumetinib (AZD6244) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in a lung cancer cell line harboring an EGFR exon 19 deletion in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 2225,
                "therapyName": "Osimertinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11318,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sprycel (dasatinib) to treatment with Tagrisso (osimertinib) resulted in increased PARP cleavage and inhibition of proliferation in lung cancer cell line harboring an EGFR exon 19 deletion in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 4946,
                "therapyName": "Dasatinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11476,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK3052230 (FP-1039) treatment resulted in greater tumor growth inhibition (56% vs 22%) in cell line xenograft models of FGFR1 amplified lung cancer compared to FGFR1 non-amplified models (PMID: 23536011).",
            "molecularProfile": {
                "id": 812,
                "profileName": "FGFR1 amp"
            },
            "therapy": {
                "id": 2899,
                "therapyName": "GSK3052230",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9409,
                    "pubMedId": 23536011,
                    "title": "Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23536011"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11767,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer patient-derived xenograft (PDX) model harboring MET amplification and MET exon 14 deletion demonstrated tumor regression when treated with Glesatinib (MGCD265) (PMID: 28765324).",
            "molecularProfile": {
                "id": 28229,
                "profileName": "MET amp MET del exon14"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11912,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KEAP1 knockout resulted in decreased sensitivity to Gilotrif (afatinib) in a lung cancer cell line harboring EGFR L858R and T790M in culture (PMID: 28145866).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9896,
                    "pubMedId": 28145866,
                    "title": "KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28145866"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12258,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 inhibited Erk signaling and proliferation of FGFR1-amplified lung cancer cell lines with undetectable Met expression in culture (PMID: 27429073).",
            "molecularProfile": {
                "id": 28613,
                "profileName": "FGFR1 amp MET dec exp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9936,
                    "pubMedId": 27429073,
                    "title": "Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27429073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12259,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGFR1-amplified lung cancer cell lines with Met expression were resistant to AZD4547 in culture (PMID: 27429073).",
            "molecularProfile": {
                "id": 28614,
                "profileName": "FGFR1 amp MET pos"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9936,
                    "pubMedId": 27429073,
                    "title": "Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27429073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12260,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rogaratinib (BAY 1163877) inhibited Erk signaling and proliferation of FGFR1-amplified lung cancer cell lines with undetectable Met expression in culture (PMID: 27429073).",
            "molecularProfile": {
                "id": 28613,
                "profileName": "FGFR1 amp MET dec exp"
            },
            "therapy": {
                "id": 2030,
                "therapyName": "Rogaratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9936,
                    "pubMedId": 27429073,
                    "title": "Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27429073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12262,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGFR1-amplified lung cancer cell lines with Met expression were resistant to Rogaratinib (BAY 1163877)  in culture (PMID: 27429073).",
            "molecularProfile": {
                "id": 28614,
                "profileName": "FGFR1 amp MET pos"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9936,
                    "pubMedId": 27429073,
                    "title": "Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27429073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12264,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MET amplification was identified as the mechanism mediating acquired AZD4547 resistance in a FGFR1 amplified lung cancer cell line in culture (PMID: 27429073).",
            "molecularProfile": {
                "id": 28587,
                "profileName": "FGFR1 amp MET amp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9936,
                    "pubMedId": 27429073,
                    "title": "Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27429073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12265,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MET overexpression and activation was identified as the mechanism mediating acquired Rogaratinib (BAY 1163877) resistance in a FGFR1 amplified lung cancer cell line in culture (PMID: 27429073).",
            "molecularProfile": {
                "id": 28586,
                "profileName": "FGFR1 amp MET over exp"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9936,
                    "pubMedId": 27429073,
                    "title": "Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27429073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12266,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 and Xalkori (crizotinib) synergistically inhibited proliferation of FGFR1 amplified lung cancer cells that acquired resistance to AZD4547 through MET amplification in culture (PMID: 27429073).",
            "molecularProfile": {
                "id": 28587,
                "profileName": "FGFR1 amp MET amp"
            },
            "therapy": {
                "id": 6398,
                "therapyName": "AZD4547 + Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9936,
                    "pubMedId": 27429073,
                    "title": "Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27429073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12267,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rogaratinib (BAY 1163877) and Xalkori (crizotinib) synergistically inhibited proliferation of FGFR1 amplified lung cancer cells that acquired resistance to Rogaratinib (BAY 1163877) through MET overexpression and activation in culture (PMID: 27429073).",
            "molecularProfile": {
                "id": 28586,
                "profileName": "FGFR1 amp MET over exp"
            },
            "therapy": {
                "id": 6399,
                "therapyName": "Crizotinib + Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9936,
                    "pubMedId": 27429073,
                    "title": "Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27429073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12325,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Glesatinib (MGCD265) inhibited Met phosphorylation and growth of MET-amplified lung cancer cells in culture (PMID: 28765324).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12326,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Glesatinib (MGCD265) inhibited Met phosphorylation and growth in lung cancer cells harboring a deletion of MET exon 14 and loss of the wild-type MET allele in culture (PMID: 28765324).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12353,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SYM015 treatment reduced Met expression and phosphorylation, resulted in growth inhibition in culture, and tumor elimination in both cell line xenograft and patient-derived xenograft (PDX) models of lung cancer with high Met expression (PMID: 28679766).",
            "molecularProfile": {
                "id": 5392,
                "profileName": "MET over exp"
            },
            "therapy": {
                "id": 4322,
                "therapyName": "SYM015",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10340,
                    "pubMedId": 28679766,
                    "title": "Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28679766"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12356,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SYM015 treatment resulted in sustained tumor growth inhibition in patient-derived xenograft (PDX) models of lung cancer harboring MET exon 14 skipping mutations (PMID: 28679766).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 4322,
                "therapyName": "SYM015",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10340,
                    "pubMedId": 28679766,
                    "title": "Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28679766"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12371,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Emibetuzumab (LY2875358) treatment resulted in initial tumor growth inhibition followed by regrowth in patient-derived xenograft (PDX) models of lung cancer harboring MET exon 14 skipping mutations (PMID: 28679766).",
            "molecularProfile": {
                "id": 26413,
                "profileName": "MET del exon14"
            },
            "therapy": {
                "id": 803,
                "therapyName": "Emibetuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 10340,
                    "pubMedId": 28679766,
                    "title": "Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28679766"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12372,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SYM015 treatment resulted in tumor growth inhibition in patient-derived xenograft (PDX) models of MET-amplified lung cancer harboring EGFR activating mutations (PMID: 28679766).",
            "molecularProfile": {
                "id": 28681,
                "profileName": "EGFR act mut MET amp"
            },
            "therapy": {
                "id": 4322,
                "therapyName": "SYM015",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10340,
                    "pubMedId": 28679766,
                    "title": "Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28679766"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12695,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a partial response in two patients with lung cancer each harboring BRAF V600E (PMID: 29247021).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10607,
                    "pubMedId": 29247021,
                    "title": "First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247021"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12696,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a partial response in a lung cancer patient harboring BRAF L597Q (PMID: 29247021).",
            "molecularProfile": {
                "id": 993,
                "profileName": "BRAF L597Q"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10607,
                    "pubMedId": 29247021,
                    "title": "First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247021"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12883,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, H3B-8800 preferentially inhibited growth of lung cancer cells harboring U2AF1 S34F compared to U2AF1 wild-type cells in culture and in cell line xenograft models (Cancer Res 2017;77(13 Suppl):Abstract nr 1185).",
            "molecularProfile": {
                "id": 23592,
                "profileName": "U2AF1 S34F"
            },
            "therapy": {
                "id": 6685,
                "therapyName": "H3B-8800",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10830,
                    "pubMedId": null,
                    "title": "H3B-8800, a novel orally available SF3b modulator, shows preclinical efficacy across spliceosome mutant cancers",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/1185.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13572,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Triolimus led to cytotoxicity and inhibited Ras/Raf/MAPK and PI3K/Akt/mTOR pathway signaling in lung cancer cells in culture, and induced apoptosis, which resulted in tumor growth inhibition, in cell line xenograft models (PMID: 22896668).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3855,
                "therapyName": "Triolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5037,
                    "pubMedId": 22896668,
                    "title": "Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22896668"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13831,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to NTRC 0066-0 compared to cell lines with wild-type CTNNB1, in culture and in xenograft models (PMID: 28751540).",
            "molecularProfile": {
                "id": 3980,
                "profileName": "CTNNB1 T41A"
            },
            "therapy": {
                "id": 3461,
                "therapyName": "NTRC 0066-0",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13835,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to Mps-BAY2b compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 3980,
                "profileName": "CTNNB1 T41A"
            },
            "therapy": {
                "id": 3451,
                "therapyName": "Mps-BAY2b",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13845,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to NMS-P715 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 3980,
                "profileName": "CTNNB1 T41A"
            },
            "therapy": {
                "id": 3107,
                "therapyName": "NMS-P715",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13846,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to BAY1161909 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 3980,
                "profileName": "CTNNB1 T41A"
            },
            "therapy": {
                "id": 3445,
                "therapyName": "BAY1161909",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13854,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to BAY1217389 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 3980,
                "profileName": "CTNNB1 T41A"
            },
            "therapy": {
                "id": 3446,
                "therapyName": "BAY1217389",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13855,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to Mps1-IN-1 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 3980,
                "profileName": "CTNNB1 T41A"
            },
            "therapy": {
                "id": 3424,
                "therapyName": "Mps1-IN-1",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13863,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A demonstrated increased sensitivity to MPI-0479605 compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540).",
            "molecularProfile": {
                "id": 3980,
                "profileName": "CTNNB1 T41A"
            },
            "therapy": {
                "id": 3458,
                "therapyName": "MPI-0479605",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11310,
                    "pubMedId": 28751540,
                    "title": "TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13870,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Camrelizumab (SHR-1210) demonstrated safety and preliminary anti-tumor activity, resulted in partial response in 33.3% (1/3) of patients with lung cancer (J Clin Onc. 2017 35:15_suppl, e15572-e15572; NCT02742935).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6137,
                "therapyName": "Camrelizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9759,
                    "pubMedId": null,
                    "title": "Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e15572"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13991,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, processed Tarloxotinib (TRLX) inhibited Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR A767_V769dup in culture, and the prodrug Tarloxotinib (TRLX) resulted in tumor regression in patient-derived xenograft (PDX) models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).",
            "molecularProfile": {
                "id": 27532,
                "profileName": "EGFR A767_V769dup"
            },
            "therapy": {
                "id": 6986,
                "therapyName": "Tarloxotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11406,
                    "pubMedId": null,
                    "title": "Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/A157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13992,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, processed Tarloxotinib (TRLX) inhibited Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR N771_H773dup in culture, and the prodrug Tarloxotinib (TRLX) resulted in tumor regression in patient-derived xenograft (PDX) models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).",
            "molecularProfile": {
                "id": 13013,
                "profileName": "EGFR N771_H773dup"
            },
            "therapy": {
                "id": 6986,
                "therapyName": "Tarloxotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11406,
                    "pubMedId": null,
                    "title": "Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/A157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13993,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, processed Tarloxotinib (TRLX) inhibited Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR S768_D770dup in culture (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).",
            "molecularProfile": {
                "id": 13009,
                "profileName": "EGFR S768_D770dup"
            },
            "therapy": {
                "id": 6986,
                "therapyName": "Tarloxotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11406,
                    "pubMedId": null,
                    "title": "Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/A157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13994,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, processed Tarloxotinib (TRLX) inhibited Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR exon 20 insertions in culture, and the prodrug Tarloxotinib (TRLX) resulted in tumor regression in patient-derived xenograft (PDX) models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).",
            "molecularProfile": {
                "id": 4039,
                "profileName": "EGFR exon 20 ins"
            },
            "therapy": {
                "id": 6986,
                "therapyName": "Tarloxotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11406,
                    "pubMedId": null,
                    "title": "Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/A157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13995,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) decreased Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR A767_V769dup in culture, bud did not affect tumor growth in patient-derived xenograft (PDX) models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).",
            "molecularProfile": {
                "id": 27532,
                "profileName": "EGFR A767_V769dup"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11406,
                    "pubMedId": null,
                    "title": "Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/A157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13996,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) decreased Egfr signaling and proliferation of patient-derived lung cancer cells harboring EGFR N771_H773dup in culture, bud did not affect tumor growth in patient-derived xenograft (PDX) models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A157).",
            "molecularProfile": {
                "id": 13013,
                "profileName": "EGFR N771_H773dup"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11406,
                    "pubMedId": null,
                    "title": "Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/A157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14041,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS6417 inhibited growth and induced apoptotic markers in a lung cancer patient-derived xenograft (PDX) model-derived cell line harboring EGFR A767_V769dup (reported as V769_D770insASV) in culture, and inhibited tumor growth and induced tumor regression in PDX models (PMID: 29748209).",
            "molecularProfile": {
                "id": 27532,
                "profileName": "EGFR A767_V769dup"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "TAS6417",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11432,
                    "pubMedId": 29748209,
                    "title": "TAS6417, a novel epidermal growth factor receptor inhibitor targeting exon 20 insertion mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29748209"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14042,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS6417 inhibited growth and induced apoptotic markers in a lung cancer cell line expressing EGFR S768_D770dup (reported as D770_N771insSVD) in culture, inhibited tumor growth and induced tumor regression in subcutaneous xenograft models, and prolonged survival in intrapulmonary xenograft models (PMID: 29748209).",
            "molecularProfile": {
                "id": 13009,
                "profileName": "EGFR S768_D770dup"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "TAS6417",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11432,
                    "pubMedId": 29748209,
                    "title": "TAS6417, a novel epidermal growth factor receptor inhibitor targeting exon 20 insertion mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29748209"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14043,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS6417 inhibited tumor growth in lung cancer patient-derived xenograft (PDX) models harboring EGFR N771_H773dup (reported as H773_V774insNPH) (PMID: 29748209).",
            "molecularProfile": {
                "id": 13013,
                "profileName": "EGFR N771_H773dup"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "TAS6417",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11432,
                    "pubMedId": 29748209,
                    "title": "TAS6417, a novel epidermal growth factor receptor inhibitor targeting exon 20 insertion mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29748209"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14044,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS6417 inhibited growth of lung cancer cell lines harboring EGFR E746_A750del in culture (PMID: 29748209).",
            "molecularProfile": {
                "id": 624,
                "profileName": "EGFR E746_A750del"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "TAS6417",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11432,
                    "pubMedId": 29748209,
                    "title": "TAS6417, a novel epidermal growth factor receptor inhibitor targeting exon 20 insertion mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29748209"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14045,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS6417 inhibited growth of a lung cancer cell line harboring EGFR L858R and EGFR T790M in culture (PMID: 29748209).",
            "molecularProfile": {
                "id": 2422,
                "profileName": "EGFR L858R EGFR T790M"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "TAS6417",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11432,
                    "pubMedId": 29748209,
                    "title": "TAS6417, a novel epidermal growth factor receptor inhibitor targeting exon 20 insertion mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29748209"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14050,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RAF709 inhibited Erk signaling and proliferation of lung cancer cells harboring NRAS Q61K in culture, and resulted in tumor regression in cell line xenograft models (PMID: 29343524).",
            "molecularProfile": {
                "id": 646,
                "profileName": "NRAS Q61K"
            },
            "therapy": {
                "id": 6995,
                "therapyName": "RAF709",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11434,
                    "pubMedId": 29343524,
                    "title": "Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29343524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14189,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD1390 inhibited Atm activity, sensitized lung cancer cells to radiotherapy in culture, and demonstrated efficacy in cell line xenograft models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104).",
            "molecularProfile": {
                "id": 20966,
                "profileName": "ATM positive"
            },
            "therapy": {
                "id": 7032,
                "therapyName": "AZD1390",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11499,
                    "pubMedId": null,
                    "title": "AZD1390, a potent and selective orally bioavailable blood-brain barrier-penetrant ATM inhibitor, radiosensitizes and improves survival of orthotopic glioma and metastatic brain tumor models",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/A104"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14737,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Poziotinib (HM781-36B) induced regression of lung tumors in mouse models harboring EGFR P772_H773insGNP (referred to as D770_N771insNPG), with no signs of progression at 12 weeks (PMID: 29686424).",
            "molecularProfile": {
                "id": 23636,
                "profileName": "EGFR P772_H773insGNP"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11486,
                    "pubMedId": 29686424,
                    "title": "Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29686424"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14744,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Poziotinib (HM781-36B) induced regression of lung tumors in mouse models harboring ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA), with no signs of progression at 12 weeks (PMID: 29686424).",
            "molecularProfile": {
                "id": 3148,
                "profileName": "ERBB2 Y772_A775dup"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11486,
                    "pubMedId": 29686424,
                    "title": "Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29686424"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15062,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cells harboring FGFR1 amplification demonstrated resistance to increasing concentrations of PD173074 in culture and was subsequently, found to have acquired AKT1 S266L (PMID: 30140389).",
            "molecularProfile": {
                "id": 30722,
                "profileName": "AKT1 S266L FGFR1 amp"
            },
            "therapy": {
                "id": 2948,
                "therapyName": "PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12589,
                    "pubMedId": 30140389,
                    "title": "Deep analysis of acquired resistance to FGFR1 inhibitor identifies MET and AKT activation and an expansion of AKT1 mutant cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30140389"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15063,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cells harboring FGFR1 amplification were sensitive to PD173074 treatment in culture, demonstrating inhibition of cell growth (PMID: 30140389).",
            "molecularProfile": {
                "id": 812,
                "profileName": "FGFR1 amp"
            },
            "therapy": {
                "id": 2948,
                "therapyName": "PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12589,
                    "pubMedId": 30140389,
                    "title": "Deep analysis of acquired resistance to FGFR1 inhibitor identifies MET and AKT activation and an expansion of AKT1 mutant cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30140389"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15064,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cells harboring FGFR1 amplification and AKT1 S266L demonstrated sensitivity to Uprosertib (GSK2141795) in culture, showing decreased phosphorylation of Akt1 targets and reduced cell growth (PMID: 30140389).",
            "molecularProfile": {
                "id": 30722,
                "profileName": "AKT1 S266L FGFR1 amp"
            },
            "therapy": {
                "id": 764,
                "therapyName": "Uprosertib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12589,
                    "pubMedId": 30140389,
                    "title": "Deep analysis of acquired resistance to FGFR1 inhibitor identifies MET and AKT activation and an expansion of AKT1 mutant cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30140389"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15984,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 did not inhibit Erk phosphorylation or proliferation of lung cancer cells harboring BRAF G469A in culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 651,
                "profileName": "BRAF G469A"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15985,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 inhibited Erk phosphorylation and proliferation of lung cancer cells harboring BRAF G466V in culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 669,
                "profileName": "BRAF G466V"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16158,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, multikinase inhibitor treatment demonstrated suboptimal clinical efficacy in RET-rearranged lung cancer patients with measurable baseline brain metastasis, resulted in confirmed intracranial response in 18% (2/11) of the patients; Alecensa (alectinib) treatment resulted an intracranial response in 1 of 2 patients (PMID: 30017832).",
            "molecularProfile": {
                "id": 1326,
                "profileName": "RET rearrange"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14285,
                    "pubMedId": 30017832,
                    "title": "Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30017832"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16161,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, multikinase inhibitor treatment demonstrated suboptimal clinical efficacy in RET-rearranged lung cancer patients with measurable baseline brain metastasis, resulted in confirmed intracranial response in 18% (2/11) of the patients; Iclusig (ponatinib) treatment resulted in no intracranial response in 3 patients (PMID: 30017832).",
            "molecularProfile": {
                "id": 1326,
                "profileName": "RET rearrange"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14285,
                    "pubMedId": 30017832,
                    "title": "Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30017832"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16548,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Capmatinib (INC280) demonstrated safety and preliminary efficacy, resulted in stable disease as best overall response in 2 patients with lung cancer (PMID: 30724423).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14616,
                    "pubMedId": 30724423,
                    "title": "Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30724423"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16772,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS0728 inhibited Erbb2 downstream signaling and proliferation of ERBB2 (HER2) amplified lung cancer cells in culture (PMID: 30787176).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 8170,
                "therapyName": "TAS0728",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14833,
                    "pubMedId": 30787176,
                    "title": "TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30787176"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16839,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TPX-0022 treatment resulted in tumor regression in patient-derived xenograft (PDX) models of lung cancer harboring MET amplification and MET exon 14 deletion (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1321).",
            "molecularProfile": {
                "id": 28229,
                "profileName": "MET amp MET del exon14"
            },
            "therapy": {
                "id": 8205,
                "therapyName": "TPX-0022",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14951,
                    "pubMedId": null,
                    "title": "TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC for treatment of cancers with abnormal HGF/MET signaling.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17241,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VB-111 treatment resulted in increased tumor lymphocyte infiltration and reduced tumor burden in animal models of lung cancer (AACR Annual Meeting 2019, Abstract 4979).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2276,
                "therapyName": "VB-111",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15256,
                    "pubMedId": null,
                    "title": "Ofranergene Obadenovec (VB-111), an anti-cancer gene therapy, induces immunologic responses in solid tumors transforming cold tumors to hot tumors",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/3761"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17379,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABX9xx inhibited Egfr and Met downstream signaling in several lung cancer cell lines harboring both EGFR and MET mutations in culture (AACR Annual Meeting 2019, Abstract 4830).",
            "molecularProfile": {
                "id": 32522,
                "profileName": "EGFR mut MET mut"
            },
            "therapy": {
                "id": 8471,
                "therapyName": "ABX9xx",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15402,
                    "pubMedId": null,
                    "title": "ABX9xx: A bispecific centyrin that synergizes to attenuate intracellular signaling in Met/EGFR positive tumors",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/3146"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01014598",
            "title": "Cisplatin in Treating Patients With Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01218867",
            "title": "Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 984,
                    "therapyName": "Anti-VEGFR2 CAR CD8 lymphocytes",
                    "synonyms": null
                },
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01366144",
            "title": "Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 954,
                    "therapyName": "Veliparib",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01386580",
            "title": "An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 974,
                    "therapyName": "2B3-101",
                    "synonyms": null
                },
                {
                    "id": 1274,
                    "therapyName": "2B3-101 + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01470209",
            "title": "A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1314,
                    "therapyName": "Buparlisib + Everolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01859026",
            "title": "A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1253,
                    "therapyName": "Binimetinib + Erlotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01935336",
            "title": "Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 877,
                    "therapyName": "Ponatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01999985",
            "title": "Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1351,
                    "therapyName": "Afatinib + Dasatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02047747",
            "title": "A Phase II Study of Dacomitinib in Progressive Brain Metastases",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 714,
                    "therapyName": "Dacomitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02155465",
            "title": "Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1858,
                    "therapyName": "Erlotinib + Ruxolitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02241369",
            "title": "Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5846,
                    "therapyName": "INO-3106 + INO-9012",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02310464",
            "title": "Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7271,
                    "therapyName": "OBI-821 + OBI-833",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02429843",
            "title": "A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 1242,
                    "therapyName": "Carotuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02433626",
            "title": "Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6962,
                    "therapyName": "COTI-2",
                    "synonyms": null
                },
                {
                    "id": 8277,
                    "therapyName": "Cisplatin + COTI-2",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02538627",
            "title": "Phase 1 Combination Study of MM-151 and MM-121",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 820,
                    "therapyName": "Seribantumab",
                    "synonyms": null
                },
                {
                    "id": 821,
                    "therapyName": "MM-151",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02675829",
            "title": "Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03188965",
            "title": "First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5962,
                    "therapyName": "BAY1895344",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03199586",
            "title": "Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7358,
                    "therapyName": "NP-G2-044",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03373760",
            "title": "Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03477162",
            "title": "Metformin Pharmacology in Human Cancers: A Proof of Principle Study",
            "phase": "Phase 0",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1031,
                    "therapyName": "Metformin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03597009",
            "title": "A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5080,
                    "therapyName": "Nivolumab + Talimogene laherparepvec",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03719768",
            "title": "Avelumab With Radiotherapy in Patients With Leptomeningeal Disease",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3144,
                    "therapyName": "Avelumab",
                    "synonyms": null
                }
            ]
        }
    ]
}